LYMPHOID NEOPLASIA

Mutations in *TLR/MYD88* pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

Alejandra Martínez-Trillos,¹ Magda Pinyol,² Alba Navarro,² Marta Aymerich,¹ Pedro Jares,² Manel Juan,³ María Rozman,¹ Dolors Colomer,¹ Julio Delgado,⁴ Eva Giné,⁴ Marcos González-Díaz,⁵ Jesús M. Hernández-Rivas,⁵ Enrique Colado,⁶ Consolación Rayón,⁶ Angel R. Payer,⁶ Maria José Terol,⁷ Blanca Navarro,⁷ Victor Quesada,⁸ Xosé S. Puente,⁸ Ciril Rozman,⁹ Carlos López-Otín,⁸ Elías Campo,^{1,10} Armando López-Guillermo,⁴ and Neus Villamor¹

¹Unitat d'Hematopatologia, Servei d'Anatomia Patològica, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and ²Unitat de Genòmica, IDIBAPS, Barcelona, Spain; ³Servei d'Inmunologia, and ⁴Servei d'Hematologia, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain; ⁵Servicio de Hematología, Hospital Clínico Universitario, Instituto de Biología molecular y celular del Cancer de Salamanca, Instituto de investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain; ⁶Servicio de Hematología, Hospital Universitario Central de Asturias, Asturias, Spain; ⁷Servicio de Hematología, Hospital Clínico de Valencia, Valencia, Spain; ⁸Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Asturias, Spain; ⁹Josep Carreras Leukemia Research Institute, Barcelona, Spain; and ¹⁰Universitat de Barcelona, Barcelona, Spain

Key Points

- Mutations in the TLR/MYD88 pathway occur in 4% of patients with CLL, and they are the most frequent in young patients.
- TLR/MYD88 mutations in CLL patients confer a good outcome, which is similar to that of the age- and gendermatched healthy population.

Mutations in Toll-like receptor (*TLR*) and myeloid differentiation primary response 88 (*MYD88*) genes have been found in chronic lymphocytic leukemia (CLL) at low frequency. We analyzed the incidence, clinicobiological characteristics, and outcome of patients with *TLR/MYD88* mutations in 587 CLL patients. Twenty-three patients (3.9%) had mutations, 19 in *MYD88* (one with concurrent *IRAK1* mutation), 2 *TLR2* (one with concomitant *TLR6* mutation), 1 *IRAK1*, and 1 *TLR5*. No mutations were found in *IRAK2* and *IRAK4*. *TLR/MYD88*-mutated CLL overexpressed genes of the nuclear factor κ B pathway. Patients with *TLR/MYD88* mutations were significantly younger (83% age ≤50 years) than those with no mutations. *TLR/MYD88* mutations were the most frequent in young patients. Patients with mutated *TLR/MYD88* CLL had a higher frequency of mutated *IGHV* and low expression of CD38 and ZAP-70. Overall survival (OS) was better in *TLR/MYD88*-mutated than unmutated patients in the whole series (10-year OS, 100% vs 62%; *P* = .002), and in the subset of patients age ≤50 years (100% vs 70%; *P* = .02). In addition, relative OS of *TLR/MYD88*-mutated patients was similar to that in the age- and

gender-matched population. In summary, *TLR/MYD88* mutations identify a population of young CLL patients with favorable outcome. (*Blood.* 2014;123(24):3790-3796)

Introduction

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults in Western countries and is characterized by the proliferation and progressive accumulation of mature clonal B lymphocytes in bone marrow, blood, and lymphoid tissues.¹ The clinical course of the disease is highly heterogeneous, with some patients requiring early treatment of disease progression while others have an indolent course that does not affect life expectancy.² Several biological features, including *IGHV* mutational status,^{3,4} cytogenetic abnormalities,⁵ or the expression of several proteins in the leukemic lymphocytes^{4,6,7} have been related to patient outcome. More recently, the use of next-generation sequencing (NGS) technologies has revealed new recurrent mutations in this disease that are present at relatively low (5% to 15%) (eg, *NOTCH1, SF3B1, ATM*) or very low frequencies (<5%) (eg, myeloid differentiation primary response

Submitted December 14, 2013; accepted March 27, 2014. Prepublished online as *Blood* First Edition paper, April 29, 2014; DOI 10.1182/blood-2013-12-543306.

A.M.-T. and M.P. contributed equally to this study.

Presented in part at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-22, 2013.

88 [*MYD88*], *XPO1*, *POT1*, *BIRC3*, *SI*).⁸⁻¹⁴ Despite the rarity of these new mutations, they could in part explain the CLL heterogeneity and help in identifying clinically relevant groups of patients.

MYD88 has been found recurrently mutated in different lymphoproliferative disorders,¹⁵⁻¹⁸ including in approximately 3% of patients with CLL.^{8,10} MYD88 is an adaptor protein of the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) that has a role in innate immune response and plays a crucial role in the homeostasis of human B cells.¹⁹ After activation of TLRs, MYD88 is phosphorylated and subsequently recruits IL-1R–associated kinases (IRAKs) and other downstream proteins such as TRAF6, finally resulting in activation of the nuclear factor κ B (NF-kB) pathway.^{8,18-20} CLL cells have a similar expression of surface TLRs and response to their activation as normal B cells, indicating that the TLR signaling

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2014 by The American Society of Hematology

The online version of this article contains a data supplement.

framework is competent in CLL cells.²¹ Although other genes of this innate immune response pathway besides *MYD88* have been found to be mutated in occasional cases of CLL, their integrative clinical impact has not been examined. In this study, we have investigated the presence of mutations in genes of the *TLR* and *MYD88* (*TLR/MYD88*) pathway previously found to be mutated in whole-genome sequencing or whole-exome sequencing (WES) (*MYD88*, *IRAK1*, *IRAK2*, *IRAK4*, *TLR2*, *TLR5*, and *TLR6*),⁸⁻¹⁰ in order to define the clinicobiological characteristics and outcome of patients carrying mutations in this pathway.

Material and methods

Patients

In all, 587 patients (353 males and 234 females) diagnosed with CLL according to World Health Organization criteria^{1.22} with available pretreatment tumor DNA were included in the study. Main characteristics of the patients, treatment given, and outcome are detailed in supplemental Data available on the *Blood* Web site. Of the total number of patients, 209 (36%) died during follow-up, with a median overall survival (OS) of 12.9 years.

All the patients gave informed consent to participate in the study according to the guidelines of the International Cancer Genome Consortium CLL project and local ethics committees. This study was conducted in accordance with the Declaration of Helsinki.

Mutational analysis

Mutations of *MYD88, IRAK1, IRAK2, IRAK4, TLR2, TLR5*, and *TLR6* were investigated by WES, as previously described, ⁹ in 243 patients. In addition, we expanded the analysis of these genes in 344 patients by Sanger sequencing. Sanger sequencing was also performed in 130 patients in which WES was done, with full agreement in the gene status. The primers and polymerase chain reaction conditions for *MYD88, IRAK1, TLR2, TLR5*, and *TLR6* are detailed in supplemental Table 1. Detailed information on mutational detection of *NOTCH1, SF3B1, TP53*, and *IGHV* is shown in supplemental Data.

Gene expression arrays and serum cytokines

The biological effects of mutations in *TLR/MYD88* were analyzed by gene expression profile and cytokine determinations, as detailed in supplemental Data.

Statistical analysis

Fisher's test or nonparametric tests were used to correlate clinical and biological variables according to *TLR/MYD88* mutations. Time to treatment (TTT) and OS curves were plotted by the Kaplan and Meier method and compared by the log-rank test. Multivariate Cox regression analysis was used to assess the independent prognostic impact of *TLR/MYD88* mutations on patient outcome.^{23,24} Relative survival was calculated by the cohort method described by Dickman et al.²⁵ Estimates of expected survival were calculated by the Ederer II method²⁶ from Spanish life tables stratified by age, sex, and calendar year, which were obtained from the Human Mortality Database (www.mortality.org). All statistical tests were two-sided, and statistical significance was considered to be significant at \leq .05. All the analyses were conducted by using SPSS 20 (http://www-01.ibm.com/software/analytics/spss/) and Stata 11 (www.stata.com) software.

Results

Mutations in the TLR/MYD88 pathway

MYD88 mutations were observed in 19 (3.2%) of 587 patients. The most frequent mutation was L265P, which was detected in 16 (84%)

Table 1. Main clinical and biological characteristics and ou	tcomes
of 587 CLL patients according to TLR/MYD88 mutations	

Characteristic or outcome	Unmutated (n=564)		Mutated (n=23)			
	No.	%	No.	%	P	
Male gender	338	60	15	65	NS	
Age, years					<.0001	
Median	61		47			
Range	24-94		32-72			
Familiar lymphoid malignancy	19/564	3	2/23	9	NS	
Binet stage					.045	
A	461	82	17	74		
В	83	15	3	13		
С	18	3	3	13		
Rai stage					.024	
0	315	56	7	30		
1-11	221	39	13	56		
III-IV	26	5	3	13		
Lymphocytes, × 10 ⁹ /L					NS	
Median	12.6		14.2			
Range	1.1-130		3.3-104			
Hemoglobin, g/L					NS	
Median	139		143			
Range	45-177		91-167			
Platelets, × 10 ⁹ /L					NS	
Median	194		183			
Range	19-791		21-332			
β ₂ -microglobulin, UNV	193/476	41	1/19	5	.001	
LDH, UNV	54/532	10	1/21	5	NS	
Monoclonal component	55/564	10	4/23	17	NS	
LDT <1 year	76/402	10	1/16	6	NS	
Mutated IGHV	255/469	54	19/21	90	.001	
<30% CD38	332/501	66	21/22	95	.002	
<20% ZAP-70	305/472	65	21/22	95	.002	
Genetics						
del(13q)(q14.3)	190/435	44	12/18	67	.09	
Trisomy 12	65/438	15	2/17	12	NS	
del(11q)(q22.3)	52/431	12	2/18	6	NS	
del(17p)(p13.1)	17/435	4	1/18	6	NS	
Mutated NOTCH1	53/498	11	0/19	0	NS	
Mutated SF3B1	35/352	10	1/15	7	NS	
Mutated TP53	16/336	5	0/17	0	NS	
Treated	301/564	53	10/23	43	NS	
10-y TTT for Binet A and B patients (%)		62		30	NS	
95% CI	57-67		8-52			
10-y rate of DLBCL for all patients (%)		7		0	NS	
95% CI	3-10					
10-y OS for all patients (%)		62		100	.002	
95% CI	55-65					

CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; LDT, lymphocyte doubling time; NS, not significant; UNV, upper normal value.

In numeric values separated by /, right values indicate number of patients with the characteristic and left values indicate total number of cases analyzed.

of the 19 patients. In 3 patients, other *MYD88* somatic mutations were found (V147L, S243N, and S219C). Additionally, 2 (0.4%) of 460 patients had *IRAK1* mutations (R666* and L692F), the latter with a concurrent *MYD88* L265P mutation; 2 (0.4%) of 469 patients had an identical mutation in *TLR2* (D327V), and one of them had a concurrent mutation in *TLR6* (P403S); 1 (0.2%) of 469 and 1 (0.2%) of 466 patients had a mutation in *TLR5* (N96K). By WES, the frequency for the *MYD88* mutant allele was between 40% and 60%, suggesting that the mutation was present in all tumor cells, with the exception of *MYD88* V147L in which the frequency was 29%, indicating that it may be subclonal. Similarly, the allelic frequency of



Figure 1. Age distribution and outcome of patients according to *TLR/MYD88* mutations. (A) Histogram representing the percentage distribution of patients according to age at diagnosis for *TLR/MYD88*-mutated (red line) and *TLR/MYD88*-unmutated (blue line) CLL patients. (B) TTT in Binet stage A and B patients (red line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-unmutated patients). (C) OS (red line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-unmutated patients). (D) Relative survival (red line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients). (D) Relative survival (red line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients).

mutated *IRAK1*, *TLR5*, *TLR6*, and one of the *TLR2* mutations was higher than 40%, whereas the other *TLR2* mutation was subclonal (frequency, 27%). No somatic mutations in *IRAK2* and *IRAK4* were identified. Overall, 23 (3.9%) of 587 patients had one or more mutations in the *TLR/MYD88* pathway.

Association of *TLR/MYD88* mutations with initial clinicobiological features

The main clinical and biological characteristics of the patients according to *TLR/MYD88* mutations are listed in Table 1. Patients with *TLR/MYD88* mutations were significantly younger (median age, 47 years; range, 32 to 72 years) than unmutated patients (median age, 61 years; range, 24 to 94 years) (P < .001) (Figure 1A). In fact, 19 (83%) of 23 *TLR/MYD88*-mutated patients were younger than age 50 years at diagnosis in comparison with 122 (22%) of 567 patients without mutations (P < .001). Patients with *TLR/MYD88* mutations had more advanced Binet and Rai stages at diagnosis, more frequently mutated *IGHV*, low CD38 expression, low ZAP-70 expression, and a trend to higher frequency of del(13q)(q14.3) (Table 1 and supplemental Table 2). Fifty-nine of 587 patients had a small monoclonal spike in the electrophoresis assay with no differences according to *TLR/MYD88*-mutated patients.

No differences were observed in the main clinicobiological characteristics between patients with *MYD88* mutations and the 4 patients with mutations in other genes of the pathway (ie, 3 were age \leq 50 years and 3 also had mutated *IGHV*).

Sera levels of IL-6, IL-1RA, CLL2, CLL3, CLL4, CLL5, and CLL11 did not differ according to the mutational status of *TLR/MYD88*. The gene expression profile of CLL with mutated *TLR/MYD88* had overexpression of genes related to the NF-κB pathway (see supplemental Methods and supplemental Results).

Clinical impact of TLR/MYD88 mutational status

The outcome of the patients according to the *TLR/MYD88* mutational status is described in Table 1. In patients with Binet stage A or B, the 10-year TTT of *TLR/MYD88*-mutated and unmutated patients was not significantly different (30% vs 62%, respectively) (Figure 1B). In addition, no differences were found in the treatment given or in the response to therapy according to *TLR/MYD88* mutational status. Time to next treatment (TTNT) measured from first response was significantly longer in patients with *TLR/MYD88* mutations than in those without mutations (median time, 11.5 vs 2.4 years, respectively; P = .04).

The OS of patients with *TLR/MYD88* mutations was significantly longer than that of unmutated patients (10-year OS, 100% vs 62%,

respectively; P = .002) (Figure 1C). Other variables associated with better OS were age ≤ 50 years at diagnosis, Binet stage A, low ZAP-70 expression, low CD38 expression, absence of adverse cytogenetics, mutated *IGHV*, absence of *NOTCH1* mutation, and absence of *SF3B1* mutation (P < .001 for all comparisons). A multivariate analysis that included age, gender, Binet stages, *IGHV*, adverse cytogenetics, *SF3B1*, *NOTCH1*, and *TLR/MYD88* mutations with a final inclusion of 438 patients showed that the most important variables for predicting OS were age (relative risk [RR], 1.054; P < .0001), *IGHV* (RR, 4.58; P < .001), Binet stage (RR, 1.67; P < .001), and adverse cytogenetics (RR, 1.7; P = .017).

To analyze the impact of *TLR/MYD88* mutations on the life expectancy of CLL patients, relative OS adjusted by general population mortality rates was calculated. As shown in Figure 1D, the life expectancy of patients with *TLR/MYD88* mutations was similar to that of the age- and gender-matched population. In contrast, CLL patients with no *TLR/MYD88* mutations had a decrease in life expectancy of 52% at 20 years.

Mutations in TLR/MYD88 in young patients

Because most patients with mutations in *TLR/MYD88* were young, we restricted the analysis to the subgroup of 146 patients (25%) age \leq 50 years at diagnosis. The clinical characteristics of the patients according to *TLR/MYD88* mutations are shown in Table 2. Young CLL patients with *TLR/MYD88* mutations had the same clinicobiological profile previously identified in the whole series with more frequent mutated *IGHV*, low CD38 expression, low ZAP-70 expression, and normal levels of β_2 -microglobulin. In addition, they showed a monoclonal spike more frequently than the remainder of the patients (21% vs 6%; *P* = .038). *TLR/MYD88* mutations (19 [13%] of 146) were the most prevalent in young patients, followed by *SF3B1* (11 [11%] of 100), *NOTCH1* (9 [6.9%] of 130), and *TP53* (2 [2.3%] of 86). Of note, *TLR/MYD88* mutations were the only ones showing a differentiated incidence according to age (13% in patients age \leq 50 years vs 0.9% in patients age >50; *P* < .001) (Figure 2A).

One hundred two patients (70%) eventually required treatment, with no significant differences observed according to *TLR/MYD88* mutations in Binet stages A and B (10-year TTT, 37% vs 74% for mutated and unmutated patients, respectively; P = .07) (Figure 2B). Response to treatment was not significantly different according to *TLR/MYD88*. TTNT was significantly longer in patients with *TLR/MYD88* mutations than in those without mutations (median time, 11.5 vs 2.0 years, respectively; P = .02).

After a median follow-up of 9.2 years (range, 0.1 to 26 years), 45 patients had died with a 10-year OS of 73%. OS was significantly better for patients with *TLR/MYD88* mutations than for the remainder of the patients (10-year OS, 100% vs 70%, respectively; P = .02) (Figure 2C). Other variables predicting better OS were Binet stage A, normal lactate dehydrogenase, normal β_2 microglobulin, mutated *IGHV*, low CD38 expression, low ZAP-70 expression, absence of *NOTCH1* mutations, and absence of *SF3B1* (P < .05 for all comparisons). In a multivariate analysis including gender, age, Binet stages, adverse cytogenetics, *IGHV*, and *TLR/MYD88*, only the mutational status of *IGHV* independently predicted OS (RR, 9.3; P < .001).

Finally, in the group of young patients, the calculation for relative OS was adjusted by age- and gender-matched population mortality rates. As depicted in Figure 2D, the life expectancy of patients with *TLR/MYD88* mutations was similar to that of the general population. In contrast, CLL patients with no *TLR/MYD88* mutations had a decrease in life expectancy of 54% at 20 years.

Table 2. Main clinical and biological characteristics of 146 patients diagnosed with CLL at age \leq 50 y according to *TLR/MYD88* mutations

	Unmutated (n = 127)		Mutated (n = 19)		
Characteristic or outcome	No.	%	No.	%	Р
Male gender	85	67	13	68	NS
Age, years					NS
Median	44		43		
Range	24-50		32-49		
Binet stage					.046
A	89/126	71	13/19	68	
В	33/126	26	3/19	16	
С	4/126	3	3/19	16	
Rai stage					
0	44/126	35	3/19	16	
1-11	77/126	61	13/19	68	.045
III-IV	5/126	4	3/19	16	
Monoclonal component	7/127	6	4/19	21	.038
β ₂ -microglobulin, UNV	40/103	39	1/15	7	.013
LDH, UNV	15/113	13	1/17	6	NS
LDT <1 y	18/79	23	1/13	8	NS
Mutated IGHV	43/99	44	15/17	88	<.001
<30% CD38	64/106	60	17/18	94	.006
<20% ZAP-70	53/100	53	18/18	100	<.001
Genetics					
del(13q)(q14.3)	34/84	40	8/14	57	NS
Trisomy 12	11/85	13	1/14	7	NS
del(11q)(q22.3)	12/83	14	1/14	7	NS
del(17p)(p13.1)	3/83	4	0/14	0	NS
Mutated NOTCH1	9/112	8	0/18	0	NS
Mutated SF3B1	10/86	12	1/14	7	NS
Mutated TP53	2/73	3	0/13	0	NS
Treated patients	92/127	73	10/19	53	NS
10-y TTT for Binet A and B patients (%)		74		37	.07
95% CI	65-83		11-64		
10-y OS for all patients (%)		70		100	.02
95% CI	65-75				

Discussion

CLL is a heterogeneous disease with subsets of patients that have different clinical behaviors. The main predictors of CLL aggressiveness currently recognized are cytogenetic abnormalities and the *IGHV* mutational status.²⁷ The recent identification of a set of new recurrent somatic mutations using NGS⁸⁻¹² has expanded the possibilities to further delineate the clinicobiological characteristics of CLL, define new predictors, and identify new therapeutic targets. The most frequent recurrent mutations in CLL patients are *NOTCH1* and *SB3F1*, detected in approximately 5% to 15% of patients at diagnosis^{28,29} and associated with poor outcome.^{10,30-32} In this scenario, the inclusion of some of these mutations in the stratification of risk of patients with CLL is warranted, and a model that integrates these mutations has been recently proposed.³³

NGS studies have revealed mutations in *MYD88* (3% to 5%) along with other genes of the same pathway at lower frequencies.⁸⁻¹² TLRs trigger an innate immune response in B cells after recognition of different pathogen-associated molecular patterns. Activation of this pathway is also considered a bridge between the innate and adaptive immunologic responses by providing costimulatory signals for the BCR.^{34,35} CLL cells express a similar pattern of TLRs as normal memory B cells, and their stimulation triggers the activation



Figure 2. Distribution of gene mutations according to age and outcome of CLL patients age \leq 50 years according to *TLR/MYD88*. (A) Distribution of the main gene mutations according to age at diagnosis (\leq 50 vs >50 years). (B) TTT in Binet stage A and B patients (red line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients). (C) OS (red line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients; blue line, *TLR/MYD88*-mutated patients). (D) Relative survival (red line, *TLR/MYD88*-mutated patients).

of the NF-κB and MAPK signaling pathways protecting CLL cells from spontaneous apoptosis.³⁴⁻³⁶ The activity of TLRs is negatively regulated by the type I transmembrane inhibitory receptor TIR8. In the TCL1 murine model of CLL, transgenic mice lacking TIR8 show an accelerated appearance of monoclonal B-cell expansions and a shorter survival experimentally supporting the implications of TLR activation in the pathogenesis of CLL.³⁷ Thus, all of the previous observations highlight the relevance of the TLR pathway in the development and progression of CLL, and this idea is reinforced by the finding of recurrent somatic mutations in genes from this pathway by NGS analysis. Concordantly, in this study, we have observed that CLL with mutations in *TLR/MYD88* had a significant overexpression of genes of the NF-κB pathway, and that these patients have an early appearance of CLL.

MYD88 is a critical adaptor protein of the IL-1R/TLR signaling pathway.¹⁹ The *MYD88* mutations described here have also been observed in other series of CLL and diffuse large B-cell lymphoma studies,^{8,10,18,33,38} and a gain of function has been demonstrated for most of them (ie, MYD88 L265P, MYD88 S243N, MYD88 S219C, and TLR2 D327V) triggering an increased production of chemokines.^{8,18,39} The remaining mutations appeared in highly conserved residues, and PolyPhen score predicted a functional damage impact in all cases. Lymph node microenvironment and cytokines play a crucial role in CLL proliferation.⁴⁰⁻⁴² However, in spite of the in vitro cytokine overproduction of the mutated cells, sera levels were similar among *TLR/MYD88*-mutated and -unmutated patients, suggesting a local effect that would be consistent with the higher frequency of Rai stages I and II in mutated patients.

TLR/MYD88 mutations were the most frequent in CLL patients age \leq 50 years reaching an incidence of 13%. It is notable that these are the only mutations described in CLL with differentiated incidence according to age. In contrast to patients with *NOTCH1* or *SF3B1* mutations, patients with *TLR/MYD88* mutations had favorable biological characteristics and outcomes. Although no differences were observed in terms of TTT, TTNT was considerably longer in these patients. Regarding survival, patients with mutated *TLR/MYD88* CLL showed remarkably good OS. Such a favorable prognosis is not merely due to age, because it was also observed in patients age \leq 50 years. Keeping in mind the low number of patients with mutations, it is not surprising that the impact on OS was not independent of other wellknown prognostic factors.

A recent study of the characteristics of young CLL patients (age \leq 55 years)⁴³ showed a higher frequency of adverse clinicobiological features and a shorter OS when compared with a sex- and age-matched population. However, the authors identified a small subgroup (15%) of young CLL patients (Rai stage 0, mutated *IGHV*, and favorable fluorescence in situ hybridization results) with an OS similar to that of the general population. Interestingly, young patients with *TLR/MYD88* mutations, even if they are at a more advanced clinical stage, had a relative OS indistinct from that of the general population, whereas a reduction of half in life expectancy was observed in young CLL patients without mutations in this pathway. This emphasizes the

clinical relevance of these mutations, which can identify approximately 10% to 15% of young CLL patients who have a very favorable outcome.

In summary, the analysis of recurrent mutations first identified by NGS could help to recognize subgroups of patients with particular features and outcomes. The current data highly suggest that *TLR/MYD88* mutations are able to distinguish a subgroup of patients with very favorable prognosis among young CLL patients. Because of the low incidence of these mutations, large series of patients, most likely in collaborative multicenter studies, are necessary to reach enough statistical power to determine its real impact in the management of patients with CLL.

Acknowledgments

This work was funded by the Spanish Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III (ISCIII) (International Cancer Genome Consortium-Chronic Lymphocytic Leukemia Genome Project), Red Temática de Investigación del Cáncer of the ISCIII (RD12/0036/0036 [E. Campo], RD12/0036/0023 [A.L.-G.], RD12/0036/0004 [D.C.], RD12/0036/0069 [M.G.-D.], PIE13/00033 [E. Campo and A.L.-G.], and RD12/0036/0067 [C.L.-O.]), Plan Nacional (SAF12/38432), and Generalitat de Catalunya

References

- Müller-Hermelink H, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:180-187.
- Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. *Nat Rev Clin Oncol.* 2010;7(9):521-532.
- Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood*. 1999;94(6): 1848-1854.
- Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood.* 1999:94(6):1840-1847.
- Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26):1910-1916.
- Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18): 1764-1775.
- Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. *Blood.* 2008; 111(2):865-873.
- Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature*. 2011; 475(7354):101-105.
- Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nat Genet.* 2011;44(1):47-52.
- 10. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic

leukemia. N Engl J Med. 2011;365(26): 2497-2506.

- Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell.* 2013;152(4): 714-726.
- Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med.* 2011;208(7):1389-1401.
- Ramsay AJ, Quesada V, Foronda M, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. *Nat Genet.* 2013;45(5): 526-530.
- Rodríguez D, Ramsay AJ, Quesada V, et al. Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients. *Hum Mol Genet*. 2013;22(11): 2273-2282.
- Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9): 826-833.
- Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2012;132(8):2118-2120.
- Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. *Acta Neuropathol.* 2011;122(6):791-792.
- Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. *Nature*. 2011;470(7332):115-119.
- Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. *Nat Rev Immunol.* 2012;12(4):282-294.
- Lin S-C, Lo Y-C, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. *Nature*. 2010;465(7300):885-890.

(2009-SGR-992). E. Campo is a researcher of the Academia Program of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya. C.L.-O. is an investigator of the Botín Foundation.

Authorship

Contribution: M.P., A.N., V.Q., D.C., X.S.P., and C.L.-O. performed sequencing analysis; M.R., N.V., M.G.-D., J.M.H.-R., B.N., C. Rayón, E. Colado, and E. Campo reviewed the pathologic data and confirmed the diagnosis; M.P. and P.J. performed the microarray analysis; M.J. performed the serum cytokine analysis; A.M.-T., J.D., E.G., A.R.P., M.J.T., and A.L.-G. reviewed clinical data; M.A. prepared and supervised the bioethics requirements; C. Rozman contributed to the statistical analysis; E. Campo, N.V., and A.L.-G. directed the research; N.V., E. Campo, and A.L.-G. wrote the manuscript; and all authors approved the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Neus Villamor, Unitat d'Hematopatologia, Servei d'Anatomia Patològica, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain; e-mail: villamor@clinic.cat.

- Muzio M, Fonte E, Caligaris-Cappio F. Toll-like Receptors in Chronic Lymphocytic Leukemia. Mediterr J Hematol Infect Dis. 2012;4(1): e2012055.
- 22. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood.* 2008;111(12): 5446-5456.
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1-39.
- 24. Cox D. Regression models and life tables. *J R* Stat Soc B. 1972;34:187-220.
- Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. *Stat Med.* 2004;23(1):51-64.
- Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. *Natl Cancer Inst Monogr.* 1961;6:101-121.
- Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-815.
- Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. *Blood.* 2012; 119(2):521-529.
- Mansouri L, Cahill N, Gunnarsson R, et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. *Leukemia*. 2013;27(2): 512-514.
- Villamor N, Conde L, Martínez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. *Leukemia*. 2013;27(5):1100-1106.

- Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood.* 2011;118(26):6904-6908.
- Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012;158(3): 426-429.
- Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. *Blood.* 2013;121(8):1403-1412.
- Muzio M, Scielzo C, Bertilaccio MTS, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. *Br J Haematol.* 2009;144(4):507-516.
- 35. Rozková D, Novotná L, Pytlík R, et al. Toll-like receptors on B-CLL cells: expression and

functional consequences of their stimulation. Int J Cancer. 2010;126(5):1132-1143.

- Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. *Haematologica*. 2011;96(11):1644-1652.
- Bertilaccio MTS, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. *Blood.* 2011;118(3):660-669.
- Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. *Leukemia*. 2014;28(1):108-117.
- Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. *Proc Natl Acad Sci U S A*. 2013;110(45):18250-18255.

 Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. *Hematology (Am Soc Hematol Educ*)

Program). 2011;2011(1):96-103.

- Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. *Blood.* 2011;117(2): 563-574.
- Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. *Haematologica*. 2011;96(3):408-416.
- Parikh SA, Rabe KG, Kay NE, et al. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. *Haematologica*. 2014; 99(1):140-147.